Early diagnostics for acute intoxication in the emergency department are about more than just identifying the cause of an overdose. They can enable timely intervention, reduce the risk of fatal outcomes, and open the door to substance use disorder treatment and recovery
Given the scale of the pediatric overdose crisis, medical students must receive early and consistent training on how to screen for substance use and engage in overdose prevention during pediatric encounters.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
SiteOne Therapeutics develops drugs that target sodium channels, the “wiring” in the body that transmits pain signals. Because SiteOne’s targets are located in the peripheral nervous system, they should not pose the same addiction risks as opioids, which hit receptors in the central nervous system.
The FDA approved RiVive, an over-the-counter version of naloxone nasal spray from Harm Reduction Therapeutics. It’s the second such approval from the FDA this year, following an affirmative decision in March for OTC Narcan.
More restrictive opioid prescribing guidelines were put in place in a rightful effort to stop a devastating crisis. But this sudden and dramatic change negatively impacted chronic pain patients who were managing their pain through prescription opioids given few other effective options.
As the pandemic rages on, the other major public health crisis in recent history has not ebbed. The opioid epidemic is worsening, but providers have kept their eye on the ball and are continuing their efforts to treat opioid use disorder and curb unnecessary prescriptions. Here is a snapshot of those efforts.
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
Covid-19 may have hampered investigations and led authorities to shift resources to more obvious frauds, attorneys said. But the pandemic also created new targets to investigate, including telemedicine and CARES Act funding.
Practice Fusion will pay $145 million to resolve criminal and civil allegations that it received kickbacks from an unnamed pharmaceutical company in exchange for building a clinical decision support system that could influence opioid prescriptions. The system generated more than 230 million alerts between 2016 and 2019, according to court documents.
The Israeli drugmaker, plus AmerisourceBergen, Cardinal Health and McKesson, reached the settlement with Ohio's Cuyahoga and Summit counties. Walgreens did not manage to reach an agreement.
Shares of the company fell 40 percent Thursday following a story late Wednesday afternoon by Bloomberg, which reported that a bankruptcy filing was a potential option.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
In a regulatory filing, the company said that the postponement was not unique to NKTR-181, though it may result in a delay in the FDA's approval decision for the drug.
Reuters reported Monday that the maker of OxyContin was considering the filing so that it could negotiate claims with plaintiffs in about 2,000 lawsuits regarding the drug.
The Boston-based company said it would not pursue a planned IPO, citing "market conditions." Nasdaq had agreed to its listing on Tuesday.
Briefing documents from the Psychopharmacologic Drugs Advisory Committee earlier this week had cast doubt on the chances of a positive vote.
The Psychopharmacologic Drugs Advisory Committee will meet on Thursday to vote on whether to recommend the FDA approve the drug, ALKS 5461, an opioid for major depressive disorder.